- Home
- IRD vs PETS Comparison
IRD vs PETS Comparison
Compare IRD & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- PETS
- Stock Information
- Founded
- IRD 2018
- PETS 1996
- Country
- IRD United States
- PETS United States
- Employees
- IRD N/A
- PETS N/A
- Industry
- IRD
- PETS Retail-Drug Stores and Proprietary Stores
- Sector
- IRD
- PETS Consumer Staples
- Exchange
- IRD NYSE
- PETS Nasdaq
- Market Cap
- IRD 59.1M
- PETS 70.4M
- IPO Year
- IRD N/A
- PETS N/A
- Fundamental
- Price
- IRD $1.18
- PETS $3.77
- Analyst Decision
- IRD Strong Buy
- PETS Sell
- Analyst Count
- IRD 3
- PETS 2
- Target Price
- IRD $6.33
- PETS $3.35
- AVG Volume (30 Days)
- IRD 295.4K
- PETS 163.8K
- Earning Date
- IRD 08-15-2025
- PETS 08-05-2025
- Dividend Yield
- IRD N/A
- PETS N/A
- EPS Growth
- IRD N/A
- PETS N/A
- EPS
- IRD N/A
- PETS 0.02
- Revenue
- IRD $13,651,000.00
- PETS $247,010,000.00
- Revenue This Year
- IRD $51.41
- PETS N/A
- Revenue Next Year
- IRD $68.84
- PETS N/A
- P/E Ratio
- IRD N/A
- PETS $220.93
- Revenue Growth
- IRD N/A
- PETS N/A
- 52 Week Low
- IRD $0.65
- PETS $2.90
- 52 Week High
- IRD $2.09
- PETS $6.85
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- PETS 59.64
- Support Level
- IRD N/A
- PETS $3.00
- Resistance Level
- IRD N/A
- PETS $3.60
- Average True Range (ATR)
- IRD 0.00
- PETS 0.19
- MACD
- IRD 0.00
- PETS 0.08
- Stochastic Oscillator
- IRD 0.00
- PETS 70.00
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.